| scholarly article | Q13442814 |
| P50 | author | Steven T. DeKosky | Q7615308 |
| M. Ilyas Kamboh | Q63929009 | ||
| Lewis Kuller | Q88077314 | ||
| William E. Klunk | Q30223705 | ||
| P2093 | author name string | Oscar L Lopez | |
| Julie C Price | |||
| Rhobert W Evans | |||
| Chester A Mathis | |||
| Jeff D Williamson | |||
| Beth E Snitz | |||
| Timothy M Hughes | |||
| Ann D Cohen | |||
| P2860 | cites work | Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. | Q40415499 |
| Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease. | Q45949729 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| The Mini-Mental State Examination. | Q52095099 | ||
| Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. | Q53236302 | ||
| Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. | Q53236904 | ||
| Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. | Q53343318 | ||
| Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry | Q59307017 | ||
| Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients | Q73462725 | ||
| Statins for the treatment of dementia | Q24236484 | ||
| Statins for the prevention of dementia | Q24241335 | ||
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease | Q28943325 | ||
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | Q29614879 | ||
| In vivo assessment of amyloid-β deposition in nondemented very elderly subjects | Q30412704 | ||
| Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. | Q30413572 | ||
| Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. | Q30433809 | ||
| The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. | Q31037161 | ||
| Plasma clusterin and the risk of Alzheimer disease | Q34176049 | ||
| Genome-wide analysis of genetic loci associated with Alzheimer disease | Q34339530 | ||
| Plasma based markers of [11C] PiB-PET brain amyloid burden | Q34427001 | ||
| Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease | Q35034130 | ||
| Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment | Q35868499 | ||
| Linking lipids to Alzheimer's disease: cholesterol and beyond | Q35875480 | ||
| Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. | Q35947072 | ||
| Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment | Q36182245 | ||
| Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. | Q36658177 | ||
| Frequent amyloid deposition without significant cognitive impairment among the elderly | Q37085957 | ||
| Oxysterols as markers of neurological disease--a review | Q37387107 | ||
| Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment | Q37775667 | ||
| Brain cholesterol metabolism, oxysterols, and dementia. | Q38053046 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 802-807 | |
| P577 | publication date | 2013-10-03 | |
| P1433 | published in | Neurobiology of Aging | Q7002141 |
| P1476 | title | Markers of cholesterol transport are associated with amyloid deposition in the brain | |
| P478 | volume | 35 |
| Q38216169 | ABCA7 in Alzheimer's Disease |
| Q46320596 | APP/Aβ structural diversity and Alzheimer's disease pathogenesis |
| Q38213077 | ATP-binding cassette transporter A1: from metabolism to neurodegeneration |
| Q36733874 | Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding |
| Q58129974 | Apolipoproteins and Alzheimer's pathophysiology |
| Q57022577 | Association between clusterin concentration and dementia: a systematic review and meta-analysis |
| Q47552491 | Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis |
| Q40274379 | Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD. |
| Q41367199 | Clinical and Sociodemographic Factors Associated with Cognitive Impairment and Neuroprotection in Diabetes Patients. |
| Q48553531 | Distinct pathways for cognitive decline in the presence of Alzheimer's disease pathology or cerebrovascular disease |
| Q36933792 | Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects |
| Q48669979 | Genetic Variations in ABCA7 Can Increase Secreted Levels of Amyloid-β40 and Amyloid-β42 Peptides and ABCA7 Transcription in Cell Culture Models |
| Q47940792 | Increased Levels of 27-Hydroxycholesterol Induced by Dietary Cholesterol in Brain Contribute to Learning and Memory Impairment in Rats |
| Q47288599 | Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later |
| Q33933612 | Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease |
| Q27014964 | Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways |
| Q48277322 | Neurobehavioral Deficits in a Rat Model of Recurrent Neonatal Seizures Are Prevented by a Ketogenic Diet and Correlate with Hippocampal Zinc/Lipid Transporter Signals |
| Q57513294 | Neuroimaging genetic risk for Alzheimer's disease in preclinical individuals: From candidate genes to polygenic approaches |
| Q27000195 | Osteoporosis and alzheimer pathology: Role of cellular stress response and hormetic redox signaling in aging and bone remodeling |
| Q27023315 | Oxidized cholesterol as the driving force behind the development of Alzheimer's disease |
| Q64075645 | Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study) |
| Q35843502 | Statins and brain integrity in older adults: secondary analysis of the Health ABC study |
| Q98204251 | The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease |
| Q37544199 | The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism |
| Q92566493 | The role of ABCA7 in Alzheimer's disease: evidence from genomics, transcriptomics and methylomics |
Search more.